Subscribe To
EBS / Emergent BioSolutions says FDA has accepted its anthrax vaccine candidate for review
EBS News
By GlobeNewsWire
October 30, 2023
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
GAITHERSBURG, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) has rescheduled its conference call to Wednesday, November more_horizontal
By Zacks Investment Research
September 7, 2023
Why Is Emergent Biosolutions (EBS) Down 22.6% Since Last Earnings Report?
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? more_horizontal
By Market Watch
August 30, 2023
Emergent Biosolutions to make Narcan opioid overdose treatment available without prescription starting in September
Emergent Biosolutions Inc. EBS, -7.92% said Wednesday its Narcan nasal spray that's an antidote for an opioid overdose will be available without a pre more_horizontal
By Seeking Alpha
August 23, 2023
Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial
Emergent BioSolutions is facing equity issuance and significant debt covenants in Q1 2024, but at its core, this is a robust pharma supplier to the U. more_horizontal
By The Motley Fool
August 22, 2023
Why Emergent BioSolutions Stock Is Tumbling Today
Emergent BioSolutions will be replaced on the S&P SmallCap 600 index. The move is a result of the company's market cap plunging since 2020. more_horizontal
By Zacks Investment Research
August 17, 2023
Down -28.45% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)
The heavy selling pressure might have exhausted for Emergent Biosolutions (EBS) as it is technically in oversold territory now. In addition to this te more_horizontal
By Zacks Investment Research
August 16, 2023
Down -26.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)
The heavy selling pressure might have exhausted for Emergent Biosolutions (EBS) as it is technically in oversold territory now. In addition to this te more_horizontal
By Zacks Investment Research
August 9, 2023
Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat
Emergent (EBS) reports wider-than-expected second-quarter loss. The company lowered its 2023 guidance for some products and services. more_horizontal